Pharmacology, Toxicology and Pharmaceutical Science
Buprenorphine
100%
Diseases
64%
Toxic Injury
52%
Naloxone
44%
Placebo
40%
Opioid Overdose
36%
Methadone
33%
Oxycodone
31%
Pharmacodynamics
28%
Pharmacokinetics
27%
Hydromorphone
22%
Randomized Clinical Trial
20%
Buprenorphine Plus Naloxone
19%
Duragesic
19%
Opiate Addiction
18%
Clinical Trial
17%
Opiate Agonist
17%
Combination Therapy
16%
Subjective Effects
15%
Drug Dependence
12%
Naltrexone
12%
Analgesic Agent
12%
Tramadol
11%
Diamorphine
10%
Drug Overdose
9%
Cannabis
9%
Levacetylmethadol
8%
Benzoylecgonine
8%
Normal Human
8%
Pandemic
8%
Cocaine Dependence
8%
Pharmacotherapy
8%
Clinical Pharmacology
7%
Tablet
7%
Cannabinoid
7%
Mortality Rate
7%
Dronabinol
7%
Oral Administration
7%
Cluster Randomized Trial
7%
Narcotic Analgesic Agent
7%
Cannabidiol
6%
Oxymorphone
6%
Randomized Controlled Trial
6%
Miosis
6%
Morphine
6%
Bioavailability
6%
Prevalence
5%
Toxicology
5%
Drug Administration
5%
Mu Opiate Receptor Agonist
5%
Medicine and Dentistry
Buprenorphine
58%
Naloxone
21%
Addictive Behavior
14%
Emergency Department
14%
Combination Therapy
14%
Randomized Clinical Trials
13%
Clinical Trial
13%
Public Health
10%
Gene Linkage
10%
COVID-19
9%
Buprenorphine Plus Naloxone
9%
Primary Outcome
9%
Opioid Dependence
9%
Methadone
9%
Placebo
9%
Telemedicine
9%
Outpatient
8%
Naltrexone
7%
Diseases
6%
Infection
6%
Substance Use Disorder
6%
Odds Ratio
6%
Hydromorphone
6%
Antimicrobial Therapy
5%
Health Care
5%
Cannabinoid
5%
